Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G5GJ
|
|||
| Former ID |
DNC001191
|
|||
| Drug Name |
R-68151
|
|||
| Synonyms |
1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H28N4O2S
|
|||
| Canonical SMILES |
CCN1C(=S)N(C(=O)C1(C)C)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)O
|
|||
| InChI |
1S/C23H28N4O2S/c1-4-26-22(30)27(21(29)23(26,2)3)19-7-5-17(6-8-19)24-13-15-25(16-14-24)18-9-11-20(28)12-10-18/h5-12,28H,4,13-16H2,1-3H3
|
|||
| InChIKey |
AHWDHLCCXRVAIC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 138331-04-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003630) | |||
| REF 2 | Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. | |||
| REF 3 | Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol. 1996;9(5):307-11. | |||
| REF 4 | Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.